摘要:
Provided herein are genetically modified non-human animals that express a human or chimeric (e.g., humanized) glucocorticoid-induced TNFR-related protein (GITR), and methods of use thereof.
摘要:
The present disclosure relates to methods of treating cancer and/or preventing metastasis thereof in subject suffering from cancer e.g., solid tumor cancers, and reagents therefor. The present disclosure also relates to methods of inhibiting or suppressing metastatic progression in a subject suffering from metastatic cancer e.g., a metastatic solid tumor cancer, and reagents therefor. In particular, the present disclosure relates to the use of compounds which inhibit MCL-1 activity for such treatment or prevention of cancer, including the use of such compounds in combination with other agents for treatment of cancer e.g., agents with inhibit activity of a SRC family kinase.
摘要:
Disclosed are methods for determining the metastatic potential of mammalian tumors and other cancers. Also disclosed are methods for altering the metastatic potential of mammalian cancers, by a) directly or indirectly increasing the level of Regnase peptide or polypeptide; b) selectively increasing the activity or specificity of Regnase peptide or polypeptide; c) selectively increasing the amount or stability of Regnase-specific mRNA; or d) selectively inhibiting one or more negative effectors of Regnase within a cancer cell in an amount and for a time effective to reduce, delay, retard, or prevent subsequent metastasis of the cancer within the body of a mammal. Also disclosed are methods for predicting cancer cell metastasis, and methods for determining the likelihood of patient outcomes by quantitating Regnase-specific expression or activity thereby providing a biomarker for determining the metastatic potential of a given cancer.
摘要:
La présente invention est relative à un embryon de gallinacé dans lequel des cellules cancéreuses ont été greffées au sein des tissus de l'embryon, caractérisé en ce que l'embryon est à un stade de développement compris entre le stade HH10 et le stade HH25 au moment de la greffe, lesdites cellules cancéreuses n'étant pas des cellules de neuroblastome, et lesdites cellules formant des tumeurs au sein de l'embryon.
摘要:
Un animal mammifère non humain choisi parmi lapin et porc, porteur d'une tumeur résultant de l'introduction orthotopique de cellules immortalisées, transformées et tumorigènes issues d'un organe d'un animal de la même espèce, lesdites cellules intégrant un ou plusieurs oncogènes, notamment les oncogènes T et t de SV40 et H-Ras V12 . Les cellules peuvent notamment être des hépatocytes ou des cellules du pancréas ou du colon. Procédé de production de ce modèle et utilisation du même pour servir de modèle d'étude permettant de mettre au point des raisonnements diagnostiques, médicaux et/ou chirurgicaux dans le cadre de la prise en charge des cancers.
摘要:
Provided here are methods for editing of a host genome to knock out or debilitate genes responsible for the growth and/or differentiation of a target organ and injecting that animal at an embryo stage with donor stem cells to complement the missing genetic information for the growth and development of the organ. The result is a chimeric animal in which the complemented tissue (human/humanized organ) matches the genotype and phenotype of the donor. Such organs may be made in a single generation and the stem cell may be taken or generated from the patient's own body. As disclosed herein, it is possible to do so by simultaneously editing multiple genes in a cell or embryo creating a "niche" for the complemented tissue. Multiple genes can be targeted for editing using targeted nucleases and homology directed repair (HDR) templates in vertebrate cells or embryos.
摘要:
Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9 IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9 IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.
摘要:
The present disclosure provides a model of human fibrolamellar hepatocellular carcinoma (FL-HCC) cells maintained as a transplantable tumor line in a host and a method to establish a transplantable human FL-HCC tumor line. Methods of ex vivo cultures of the FL-HCC are provided. Methods of diagnosing and treating FL-HCC tumors are also provided.